Company Overview and News

 
DBO / PowerShares DB Oil Fund FORM 10-Q (Quarterly Report)

2018-08-08 sec.gov
dbs-10q_20180630.htm UNITED STATES
DBO

 
DBO / PowerShares DB Oil Fund FORM 10-Q (Quarterly Report)

2018-08-08 sec.gov
dbs-10q_20180630.htm UNITED STATES
DBO

2
Is PowerShares DB Oil Fund (DBO) a Hot ETF Right Now?

2018-06-12 zacks
The PowerShares DB Oil Fund (DBO - Free Report) made its debut on 01/05/2007, and is a smart beta exchange traded fund that provides broad exposure to the Energy ETFs category of the U.S. equity market.
DBO TRI

6
DBO / PowerShares DB Oil Fund FORM 8-K (Current Report)

2018-06-04 sec.gov - 5
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
DBO

1
DBO / PowerShares DB Oil Fund PROSPECTUS SUPPLEMENT NO. 3 (Prospectus)

2018-06-04 sec.gov
Prospectus Supplement No. 3 Filed Pursuant to Rule 424(b)(3) Registration Nos. 333-209437 333-209437-01 333-209437-02 333-209437-03 333-209437-04 333-209437-05 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated March 8, 2018) <
DBO

1
DBO / PowerShares DB Oil Fund PROSPECTUS SUPPLEMENT NO. 2 (Prospectus)

2018-05-25 sec.gov
Prospectus Supplement No. 2 Filed Pursuant to Rule 424(b)(3) Registration Nos. 333-209437 333-209437-01
DBO

3
President Trump Impacts Iran and Crude Oil Futures

2018-05-10 marketrealist
On May 8, President Trump said that the US is exiting the Iranian nuclear deal. President Trump plans to impose new sanctions on Iran.
DBO LPI MRO

1
DBO / PowerShares DB Oil Fund 10-Q (Quarterly Report)

2018-05-08 sec.gov
dbo-10q_20180331.htm UNITED STATES
DBO

1
DBO / PowerShares DB Oil Fund 10-Q (Quarterly Report)

2018-05-08 sec.gov
dbs-10q_20180331.htm UNITED STATES
DBO

1
DBO / PowerShares DB Oil Fund 10-Q (Quarterly Report)

2018-05-08 sec.gov
dbs-10q_20180331.htm UNITED STATES
DBO

27
How to Play Oil's Surge with ETFs

2018-05-07 zacks
Oil prices surged to their highest levels since 2014 amid increasing demand, rising geopolitical risks and concerns that Trump administration could withdraw from the Iran nuclear deal.
USO DBO TXN UNP USL

8
Will US Gasoline and Distillate Inventories Boost Oil Prices?

2018-05-03 marketrealist
The API (American Petroleum Institute) released its US gasoline and distillate inventory data on May 1. The API reported that US gasoline inventories increased by 1.6 MMbbls (million barrels) on April 20–27. Analysts estimate that US gasoline inventories could have dropped by ~0.6 MMbbls during the same period.
DBO KMI NFX KMR KMRFZ CVB

2
DBO / PowerShares DB Oil Fund PROSPECTUS SUPPLEMENT (Prospectus)

2018-04-27 sec.gov - 1
Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration Nos. 333-209437 333-209437-01
DBO

17
With A Lofty Roll Yield, PowerShares DB Oil Fund Looks Attractive

2018-04-27 seekingalpha
Commodity futures offer higher returns when in backwardation, as investors are able to earn a positive roll yield.
DBO USO

1
US Dollar Index Is near a 4-Month High

2018-04-25 marketrealist
The US Dollar Index rose ~1.4% to 90.7 on April 17–24. The index is near the highest level since January 12. The active WTI crude oil futures increased ~1.7% on April 17–24. The appreciating US Dollar Index limited the upside for oil prices during this period.
DBO

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to DGL / PowerShares DB Gold Fund on message board site Silicon Investor.

Digital Ally Inc. - DGLY Digital Ally Inc. - DGLY Digital Ally Inc. - DGLY Secured Digital Applications Inc. (SDGL.OB) Secured Digital Applications Inc. (SDGL.OB) Secured Digital Applications Inc. (SDGL.OB)
UCOMA UnitedGlobalCom UCOMA UnitedGlobalCom UCOMA UnitedGlobalCom BNDGL (ficticious stock) - the Big u0026#034;BOONDOGGLEu0026#034;.. BNDGL (ficticious stock) - the Big u0026#034;BOONDOGGLEu0026#034;.. BNDGL (ficticious stock) - the Big u0026#034;BOONDOGGLEu0026#034;..
Fledgling Newsletter Recommendations Fledgling Newsletter Recommendations Fledgling Newsletter Recommendations
CUSIP: 73936B606